Fig. 3From: Application of lipid nanovesicle drug delivery system in cancer immunotherapyReprint with permission from [54]. Copyright 2021, American Chemical SocietyCHI/BMS-202@lipF-Mediated Synergistic TNBC Treatment. a Schematic Illustration of CHI/BMS-202@lipF-Mediated Synergistic TNBC Treatment. b Treatment schedule for CHI/BMS-202@lipF-mediated antitumor combination therapy in vivo. c Average tumor volume. d Survival rate of mice with various treatments (n = 8).Back to article page